4 results on '"Malavasi, N."'
Search Results
2. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
- Author
-
Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, Colucci G, Gerunda GE, Depenni R, Zironi S, Fontana A, Pettorelli E, Luppi G, and Conte PF
- Subjects
- Adult, Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bevacizumab, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Fluorouracil therapeutic use, Follow-Up Studies, Humans, Leucovorin administration & dosage, Leucovorin adverse effects, Leucovorin therapeutic use, Liver Neoplasms secondary, Male, Middle Aged, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds adverse effects, Organoplatinum Compounds therapeutic use, Positron-Emission Tomography, Tomography, X-Ray Computed, Antibodies, Monoclonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Liver Neoplasms drug therapy
- Abstract
Background: In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS)., Methods: In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+ five of bevacizumab. Patients not achieving resectability received six additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment., Results: From September 2005 to July 2009, 21 patients were enrolled (Male/Female: 15/6; median age: 65 years). An objective response (OR) was documented in 12 cases (57.1%; complete responses (CRs): 3, partial response (PR): 9); one patient died from toxicity before surgery. Thirteen patients underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six patients (46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months. Patients achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS) (median PFS: 22 vs 14 months, P=0.001)., Conclusions: FOLFOX6+bevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early changes in PET-CT seem to be predictive of longer PFS.
- Published
- 2011
- Full Text
- View/download PDF
3. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
- Author
-
Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, Depenni R, Zironi S, Del Giovane C, Luppi G, and Conte PF
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Disease-Free Survival, ErbB Receptors antagonists & inhibitors, Female, Fluorouracil administration & dosage, Gene Dosage, Humans, Male, Middle Aged, Mutation, Neoadjuvant Therapy, Prognosis, Rectal Neoplasms drug therapy, Rectal Neoplasms mortality, Rectal Neoplasms radiotherapy, Genes, erbB-1, Genes, ras, Rectal Neoplasms genetics
- Abstract
Background: Epidermal growth factor receptor (EGFR), evaluated by immunohistochemistry, has been shown to have prognostic significance in patients with colorectal cancer. Gene copy number (GCN) of EGFR and KRAS status predict response and outcome in patients treated with anti-EGFR therapy, but their prognostic significance in colorectal cancer patients is still unclear., Methods: We have retrospectively reviewed the baseline EGFR GCN, KRAS status and clinical outcome of 146 locally advanced rectal cancer (LARC) patients treated with preoperative chemoradiotherapy. Pathological response evaluated by Dworak's tumour regression grade (TRG), disease-free survival (DFS) and overall survival (OS) were analysed., Results: Tumour regression grade 4 and TRG3-4 were achieved in 14.4 and 30.8% of the patients respectively. Twenty-nine (19.9%) and 33 patients (19.2%) had an EGFR/nuclei ratio >2.9 and CEP7 polisomy >50% respectively; 28 patients (19.2%) had a KRAS mutation. Neither EGFR GCN nor KRAS status was statistically correlated to TRG. 5-year DFS and OS were 63.3 and 71.5%, respectively, and no significant relation with EGFR GCN or KRAS status was found., Conclusion: Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative chemoradiation.
- Published
- 2010
- Full Text
- View/download PDF
4. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
- Author
-
Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, and Conte P
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Benzenesulfonates adverse effects, Bile Duct Neoplasms drug therapy, Bile Duct Neoplasms pathology, Biliary Tract Neoplasms pathology, Carcinoma pathology, Cholangiocarcinoma drug therapy, Cholangiocarcinoma pathology, Disease-Free Survival, Drug Eruptions etiology, Fatigue chemically induced, Female, Gallbladder Neoplasms drug therapy, Gallbladder Neoplasms pathology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Niacinamide analogs & derivatives, Phenylurea Compounds, Protein Kinase Inhibitors adverse effects, Pyridines adverse effects, Salvage Therapy, Sorafenib, Antineoplastic Agents therapeutic use, Benzenesulfonates therapeutic use, Biliary Tract Neoplasms drug therapy, Carcinoma drug therapy, Protein Kinase Inhibitors therapeutic use, Pyridines therapeutic use
- Abstract
Background: Advanced biliary tract carcinoma has a very poor prognosis, with chemotherapy being the mainstay of treatment. Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-beta, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma., Methods: We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma. Sorafenib was administered at a dose of 400 mg twice a day. The primary end point was the disease control rate at 12 weeks., Results: A total of 46 patients were treated. In all, 26 (56%) had received chemotherapy earlier, and 36 patients completed at least 45 days of treatment. In intention-to-treat analysis, the objective response was 2% and the disease control rate at 12 weeks was 32.6%. Progression-free survival (PFS) was 2.3 months (range: 0-12 months), and the median overall survival was 4.4 months (range: 0-22 months). Performance status was significantly related to PFS: median PFS values for ECOG 0 and 1 were 5.7 and 2.1 months, respectively (P=0.0002). The most common toxicities were skin rash (35%) and fatigue (33%), requiring a dose reduction in 22% of patients., Conclusions: Sorafenib as a single agent has a low activity in cholangiocarcinoma. Patients having a good performance status have a better PFS. The toxicity profile is manageable.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.